Specialization in Gastric Cancer Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05280665|
Recruitment Status : Recruiting
First Posted : March 15, 2022
Last Update Posted : March 15, 2022
|Condition or disease||Intervention/treatment|
|Stomach Neoplasms Gastric Cancer||Other: Specialization|
Specialization is having sufficient and effective knowledge on a subject. Today, in the medical world, specialization is defined as having competent knowledge on a disease, and in recent years, the benefit of specialization has begun to be emphasized. Initially, it was defined as a branching and over the years, internal and surgical departments were divided into sub-areas. In surgical sciences, these fields are determined as traumatology, breast-endocrine surgery and gastrointestinal system surgery. This branching has brought a different perspective and approach to diseases and has made it possible to be more effective in the management of diseases. In recent years, a specialization approach on diseases and organ systems has developed within these branches. In surgery, surgeons specialized on many organs such as pancreatic surgery, colorectal surgery, gastric surgery, breast surgery, ovarian surgery have increased the efficiency in the management of diseases and the survival and disease-free survival rates of the patients have increased, and the postoperative morbidity and mortality rates have decreased.
Gastric cancer is one of the most common malignant cancers. It is the fifth most common cause of cancer-related death worldwide. Despite advances in diagnosis and treatment methods, patients may still be diagnosed late, and patients still have a poor prognosis due to the biology of gastric cancer. Even in properly treated patients, five-year survival rates are around 20-30%. With the development of surgical techniques and disease management, clinical outcomes of the disease have improved and mortality has been reduced. In the studies, the definition of gastric surgeon was created and it was determined that the mortality decreased proportionally with the increase in the patient volume of the surgeon. In gastric cancer surgery, there are mostly studies on the number of surgeon patients and the number of hospital patients. Post-hoc analysis of hospital volume on patients included in the CRITICS study showed a 13.1% increase in survival in high-volume hospitals compared to low-volume hospitals. The number of annual resections ≥21 was determined as the definition of high-volume hospital. In addition, it was determined that there was a decrease in mortality as the number of annual cases increased in high-volume hospitals. In another study, it was seen that there was an improvement in the mortality of medium and high volume hospitals compared to low volume hospitals. The majority of studies in gastric cancer surgery have focused on hospital volume and surgeon volume. There are no data on the specialization of the surgeon other than a study based in Japan.
In this study, it was aimed to evaluate the effect of specialization in gastric cancer surgery on short- and long-term clinical outcomes.
|Study Type :||Observational|
|Estimated Enrollment :||274 participants|
|Official Title:||The Impact of Specialization on Clinical Outcomes in Gastric Cancer Surgery|
|Actual Study Start Date :||February 14, 2022|
|Estimated Primary Completion Date :||September 2022|
|Estimated Study Completion Date :||February 2023|
The non-specialized group
Patients who were operated by a non-specialized surgeon. Non-specialized surgeons were defined as general surgeon who does not have the characteristics of a specialized gastric cancer surgeon.
The specialized group
Patients who were operated by a specialized gastric cancer surgeon. Specialized gastric cancer surgeons were defined as surgeons who meet all of the criteria for a specialized gastric cancer surgeon.
Other Name: Gastric cancer surgery
- 30-day mortality [ Time Frame: 30 days after the operation (postoperative hospital stay ≤ 30 days) or operation to first discharge from hospital (postoperative hospital stay > 30 days) ]Death from any cause within 30 days after surgery or at any time if not discharged from hospital
- 90-day mortality [ Time Frame: 90 days after the operation (postoperative hospital stay ≤ 90 days) or operation to first discharge from hospital (postoperative hospital stay > 90 days) ]Death from any cause within 90 days after surgery or at any time if not discharged from hospital
- Postoperative complication rate [ Time Frame: Within 30 days after the operation ]Any complications (graded by the Clavien-Dindo classification) occurred in the postoperative period
- Postoperative major complication rate [ Time Frame: Within 30 days after the operation ]≥grade-III Clavien-Dindo complications occurred in the postoperative period
- Readmission [ Time Frame: Within 30 days after the operation ]Readmission requiring re-hospitalization for any complications after discharge
- 3-year overall survival [ Time Frame: 3 years after surgery ]Death from any cause is defined as an event.
- 3-year recurrence-free survival [ Time Frame: 3 years after surgery ]Death from any cause or the recurrence of gastric cancer are an event.
- Hospital stay [ Time Frame: From the date of surgery until the date of hospital discharge, assessed up to 90 days after the operation ]Duration of postoperative hospital stays
- Failure-to-cure [ Time Frame: Within 30 days after the operation ]futile surgery due to intraoperative distant metastasis/irresectability, OR microscopically or macroscopically incomplete resection OR 30-day mortality
- Neoadjuvant treatment usage [ Time Frame: Within the three months before surgery ]Neoadjuvant treatment usage rates in patients undergoing surgical treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05280665
|Contact: Ali Guner, MD||+90 (462) 377 54 firstname.lastname@example.org|
|Principal Investigator:||Ali Guner, MD||Karadeniz Technical University Faculty of Medicine|